Nortriptyline Should NOT Be Used to Treat Restless Legs Syndrome
Nortriptyline is not recommended for RLS treatment and does not appear in the 2025 American Academy of Sleep Medicine (AASM) clinical practice guidelines as an evaluated or recommended therapy. 1
Why Nortriptyline Is Not Recommended
The most recent and authoritative 2025 AASM guidelines comprehensively reviewed RLS treatments and nortriptyline was not included among the 22 specific recommendations made for adults or children with RLS. The guideline evaluated numerous medications including dopamine agonists, anticonvulsants, opioids, benzodiazepines, and other agents—but nortriptyline was notably absent from this systematic review.
Critical Context: Tricyclic Antidepressants May Worsen RLS
While not explicitly stated in the guidelines, tricyclic antidepressants (TCAs) like nortriptyline are generally recognized in clinical practice as potentially worsening RLS symptoms due to their effects on dopamine and other neurotransmitter systems. The FDA label for nortriptyline 2 lists its approved indication as depression only—not RLS—and includes significant warnings about cardiovascular effects, anticholinergic side effects, and seizure threshold lowering.
What the Limited Research Shows
Two small studies from India 3, 4 compared nortriptyline 25 mg to clonazepam 0.5 mg in women over 40 with RLS:
- Nortriptyline showed some improvement in RLS frequency but was numerically inferior to clonazepam at 4 weeks
- Both drugs showed comparable results at 8 weeks
- However, the 2025 AASM guidelines recommend AGAINST clonazepam (conditional recommendation, very low certainty of evidence) 1
This means even if nortriptyline performed comparably to clonazepam, it would still fall into the "not recommended" category by current standards.
What You Should Use Instead
First-Line Treatments (Strong Recommendations):
α2δ calcium channel ligands 1:
- Gabapentin enacarbil (strong recommendation, moderate certainty)
- Gabapentin (strong recommendation, moderate certainty)
- Pregabalin (strong recommendation, moderate certainty)
IV iron therapy when ferritin <75-100 ng/mL 1:
- IV ferric carboxymaltose (strong recommendation, moderate certainty)
- IV low molecular weight iron dextran (conditional recommendation)
- IV ferumoxytol (conditional recommendation)
Second-Line Options (Conditional Recommendations):
- Oral ferrous sulfate for appropriate iron status 1
- Extended-release oxycodone and other opioids (conditional recommendation, moderate certainty) 1
- Dipyridamole (conditional recommendation, low certainty) 1
Important Paradigm Shift:
Dopamine agonists are now recommended AGAINST for standard use due to augmentation risk 1, 5, 6, 7, 8, representing a major change from 2012 guidelines.
Clinical Pitfalls to Avoid
- Do not use antidepressants empirically for RLS—they are not evidence-based and may worsen symptoms
- Always check iron status first: ferritin and transferrin saturation should guide iron supplementation even without anemia
- Avoid dopamine agonists as first-line therapy despite their historical use—augmentation is a serious long-term complication
- Screen for secondary causes: medications (especially antidepressants, antihistamines, antipsychotics), iron deficiency, renal disease